Your prediction
Sonnet Biotherapeutics Holdings Inc. Stock
Our community identified positive and negative aspects for Sonnet Biotherapeutics Holdings Inc. stock for the coming years. 2 users see the criterium "Worthwhile Investment for the next years" as a plus for the Sonnet Biotherapeutics Holdings Inc. stock. On the other hand our users think that "Expected dividend yield" could be a problem in the future.
Pros and Cons of Sonnet Biotherapeutics Holdings Inc. in the next few years
Pros
?
B****
?
W********* I********* f** t** n*** y****
?
S********** s********
Cons
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Sonnet Biotherapeutics Holdings Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Sonnet Biotherapeutics Holdings Inc. | - | - | - | - | - | - | - |
| J D Wetherspoon plc | 1.080% | -0.535% | 12.048% | 11.377% | 12.727% | 24.166% | -29.170% |
| SSP Group plc | 0.000% | 1.754% | 10.476% | 34.104% | 6.422% | -12.782% | -21.886% |
| Soup Restaurant Group Ltd | 2.080% | -5.882% | -7.692% | -40.000% | -44.828% | -38.462% | -43.529% |
Comments
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $20.00 price target on the stock.
Show more
Ratings data for SONN provided by MarketBeat
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $20.00 price target on the stock.
Show more
Ratings data for SONN provided by MarketBeat
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) had its price target lowered by analysts at Chardan Capital from $30.00 to $20.00. They now have a "buy" rating on the stock.
Show more
Ratings data for SONN provided by MarketBeat